Session 1: Sunday July 1, PM (7:30-10) | Structure-Function and Chemistry |
Discussion leader: Mark Nelson, Paratek Pharmaceuticals, Inc.
Mark Nelson, Ph.D., Paratek Pharmaceuticals, Inc.
Chemical and biological properties of the tetracyclines
William Heggie, Ph.D. , Hovione Chemical Industrial Production of tetracyclines
P.E. Sum, Ph.D. , American Home Products
The Discovery and Development of Glycylcyclines as a New Generation of Tetracycline Antibacterial Agents
Michael Draper, Ph.D., Paratek Pharmaceuticals
Antiparasitic Properties of the Tetracyclines
Session 2: Monday July 2, AM | Biological Functions of Antibiotics |
Discussion leader: Stuart B. Levy, M.D. , Tufts University School of Medicine
Siegfried Schneider, Ph. D. , University of Erlangen
Proton and Metal Binding of TCs
Christian Berens , University of Erlangen
RNA and Tc Binding
Howard Shapiro, M.D. , Shapiro Laboratories
Assessment of Antibiotic Effects on Membranes of Individual Bacteria Using Flow Cytometry
David Auld , Harvard University Medical School
Zinc Binding Sites in Enzymes
Shing Ming Lee, Ph.D. , SUNY Stonybrook
Biologic efficacy of a new chemically modified non-antimicrobial tetracycline - Son of CMT-3
Session 3: Monday July 2, PM | Tetracyclines, CMTs and MMP Inhibition |
Discussion leader; Lorne M. Golub, D.M.D., M.Sc. M.D. (Hon.) , SUNY Stonybrook
Lorne Golub, DDS , SUNY Stonybrook
Non-antimicrobial tetracycline formulations reduce local (periodontal) and
systemic bone loss during post-menopausal osteoporosis
Y. Liu, Ph.D., SUNY Stonybrook
Antifungal Properties of CMTs
Saijun Fan, Ph.D., Long Island Jewish Medical Center
Suppresiion of tumor cell invasion and migration by CMTs: new mechanisms
Brad Zerler, Ph.D. , Collagenex Pharmaceuticals From bench to clinical trials: Odyssey of a chemically modified tetracycline
Bruce Dezube, M.D., Beth Israel Deaconess Medical Center
COL-3 in patients with AIDS-related Kaposi's sarcoma: a national cancer institute/AIDS malignancy consortium study
Session 4: Tuesday, July 3, AM | MMPs, Collagen and inflammatory diseases |
Discussion leader; Robert Greenwald, M.D.
Robert Greenwald, M.D. , LIJMH
Inhibition of MMPs by chemically modified tetracyclines
Robert Freidlander, M.D. , Harvard Medical School
Role of caspases in neurodegeneration
Rob Ashley, Ph.D. , Collagenex Pharmaceuticals
Periostat: Clinical evidence of the non-antimicrobial properties of the tetracyclines
Arnon Nagler, Ph.D., Hadassah University Hospital
Halofuginone: a novel inhibitor of collagen type I: therapeutic potential for graft versus host disease and other fibrotic states
Mark PInes, Ph.D., Institute of animal science, the volcani canter
Halofuginone: inhibition of type I collagen gene expression by halofuginone as a modality to prevent and treat surgical adhesions and liver fibrosis
Session 5: Tuesday, July 3, PM | Tetracyclines and Molecular Mechanisms |
Discussion leader; Maria Ryan, SUNY Stonybrook
Maria Ryan, DDS , Ph.D. , SUNY Stonybrook
A new therapeutic approach for the management of diabetic complications using tetracycline compounds
Juha Yrjanheikki, Ph.D. , University of Kuopio
Minocycline and microglial activation pathways in brain ischemia
Christopher Ritchlin, M.D. , Univ of Rochester Medical School
The effects of TCs and CMTs on cytokine production
Robert Thompson, M.D., Washington University school of medicine
Role of Tcs in the treatment of abdominal aortic aneurysms
Session 6: Wednesday, July 4, AM | Tetracycline and Repressor Function |
Discussion leader; Wolfgang Hillen
Hermann Bujard, Prof. Dr. , University of Heidelberg
Tetracycline Controlled Transcription Activation in Eukaryotes: Advances and Applications
Wolfgang Hillen , University of Erlangen
Gene regulation by tetracyclines: evolution in bacteria and tailoring for applications in eukaryotes
Winfried Hinrichs, Ph.D., Ernst-Moritz-Arndt-Universitat Greifswald
Structure and Function of Tet repressor/Tetracycline interaction
Andrew Farmer, Ph.D., Clontech Laboratories
Tetracycline-regulated gene expression systems: the subtlety and power of inducible expression systems
Session 7: Wednesday, July 4, PM | Tetracycline and Eukaryotic Systems |
Discussion leader; Hermann Bujard, Prof. Dr.
Dean Felsher, M.D. Ph. D. , Stanford University
Conditional Oncogene Activation in Transgenic Mice
Luke Alphey, Ph. D. , University of Oxford
Insect population control using a tetracycline-repressible dominant lethal
Ben Berkhout, Ph.D., University of Amsterdam
Doxycycline-dependent HIV-1
Session 8: Thursday, July 5, AM | Tcs, MMPs, Cytokines and other Secondary Messengers |
Discussion leader; Timo Sorsa, DDS, Ph.D.
Timo Sorsa, DDS, Ph.D. , University of Helsinki
Use of MMP-diagnostic test in periodontitis and peri-implantitis to monitor the MMP-inhibition medication
Gary Nieman, SUNY Health Science Center
Use of non-antibiotic tetracyclines to prevent acute lung injury (ALI)
Lawrence de Garavilla, Ph.D., RW Johnson Pharm. Research Institute
Effects of antibiotics on platelet aggregation
Session 9: Thursday, July 5, PM | Tcs and Cancer |
Discussion leader; Bal Lokeshwar, Ph. D. , University of Miami
Bal Lokeshwar, Ph.D. , University of Miami
CMTs and control of metastatic cancer
Michelle Rudek , National Cancer Institute
Clinical pharmacology of COL-3 in patients with refractory metastatic cancer
Sandy Simon, Ph.D. , SUNY Stonybrook
Downregulation of the invasive phenotype of tumor cell lines by chemically modified tetracyclines
|